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Abstract Low density lipoprotein receptor domains (LDLrs) 
represent a large cell surface receptor superfamily of consensus 
length 39 residues. Alignment of 194 sequences indicated highly 
conserved Cys and Asp/Glu residues, and a consensus econdary 
structure with three fl-strands was predicted. Sequence threading 
against known protein folds indicated consistency with small fl- 
sheet proteins. Complement factor I contains two LDLrs, and the 
second of these was successfully expressed using a bacterial 
pGEX system. FT-IR spectroscopy on this indicated a small 
amount of fl-sheet together with turns and loops. LDLr is pro- 
posed to have a fl-sheet structure in which the five biologically 
important Asp/Glu residues are located on an exposed loop. 
Key words: LDLr  domain; FT-IR spectroscopy; Secondary 
structure prediction; Protein fold recognition; fl-Sheet protein 
basic amino acids in other ligands [2]. LDLr-3 to LDLr-7 in the 
LDL receptor are essential for apoprotein B binding, and 
LDLr-5 is essential for apoprotein E binding. In the ~2M recep- 
tor, a fragment with eight LDLr domains binds to ~2 M. 
A powerful strategy to analyse protein structures has been 
developed, based on the joint use of (a) averaged secondary 
structure predictions to define structural elements, (b) sequence 
threading against known protein folds to identify related pro- 
tein folds, and (c) spectroscopy to identify the secondary struc- 
ture [6,7]. By this approach, we show that LDLr  contains turns 
and loops with a small amount of fl-strand, and propose that 
the biologically important Asp/Glu residues are located on a 
surface loop. 
2. Materials and methods 
1. Introduction 
The low density lipoprotein receptor domain (LDLr) is a 
cysteine-rich repeat of approximately 40 amino acids. This was 
first identified in the low density lipoprotein cell surface recep- 
tor protein [1,2]. LDLr  is also found in factor I [3,4] (Fig. 1), 
C6, C7, C8 and C9 of complement, and in members of the c%M 
receptor family protein [2]. LDLr  occurs as groups of repeats 
in the cell surface receptors, but as single or double repeats in 
the complement proteins. The domain is encoded by individual 
exons. Mutations in the LDLr  allele are associated with familial 
hypercholesteremia, a disease which leads to premature athero- 
sclerosis. 
LDLr  is characterised by six Cys residues and a conserved 
cluster of acidic residues. The disulphide bridge pairings and 
the atomic structure are unknown. The complement LDLrs 
have an unknown function, although in C9 they may aid forma- 
tion of the membrane attack complex. C9 may be both a ligand 
and a receptor during its polymerisation, as a region within C9 
is similar to the apoprotein E binding site for the LDL receptor 
[5]. In the cell surface receptors, the domain is involved in 
ligand binding. The conserved acidic residues interact elec- 
trostatically with basic regions in apoproteins B and E of 
VLDL and LDL, and are thought to bind to regions rich in 
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Abbreviations: LDLr2, second low density lipoprotein receptor domain 
of factor I; FT-IR, Fourier transform infrared; CD, circular dichroism; 
NMR, nuclear magnetic resonance. 
2.1. Alignments and structure predictions 
A total of 194 LDLr sequences were extracted from the ENTREZ 
CD-ROM database (Release 14, December 1994). These were initially 
aligned using the program MULTAL [8], and adjusted manually to 
maximise the alignment of conserved or chemically similar esidues [9]. 
These residues were defined as follows: tiny, G, A, S; aliphatic, I, L, V, 
M; aromatic, H, F, Y, W; positive, R, H, K; negative, D, E; hydroxyl, 
S, T; amide, N, Q [10]. Averaged structure predictions were calculated 
from the sequence alignments using the Chou-Fasman and fl-biased 
GOR I and GOR III statistical methods [11-14], and the PHD neural 
network method [15]. Hydropathy analyses were based on summation 
of the total of hydrophobic or hydrophilic residues at each position [16], 
defined on the basis of consensus values [17]. Solvent accessibilities were 
predicted by the PHD neural network method [18]. The LDLr se- 
quences were subjected to summation of pairwise energy and solvation 
terms to score their similarity with known protein folds using the pro- 
gram THREADER [19]. 
2.2. Cloning of the LDLr2 coding sequence from factor I 
The LDLr2 coding sequence of factor I (residues 240-276 [3]) was
amplified from a cDNA clone [3] by PCR at an annealing temperature 
of 42°C with the following primers: 5' oligonucleotide GCA TGC CAA 
GGC AAA GGC TTC, 3' oligonucleotide CGG ATC CTA TGC ACA 
GCC AAC TTC ATC TTC. The underlined region in the 3' oligonucle- 
otide corresponds to a BamHI restriction site used to identify positive 
clones and the region shown in bold corresponds toa translation termi- 
nation codon. The PCR product was ligated into the fusion protein 
expression vector pGEX-3X (Pharmacia), which had been digested 
with Sinai, and transformed into the E. coli strain JM109. Recombinant 
colonies were confirmed by PCR, digestion of plasmid DNA with 
BamHI and DNA sequencing using the USB Sequenase enzyme (V r- 
sion 2.0) and the PCR primers. 
An overnight bacterial culture was diluted 1:10 in fresh LB-medium 
and protein expression was induced with 0.1 mM IPTG when the OD600 
of the culture was 0.6. The culture was incubated for a further three 
hours and pelletted. The cells were resuspended in 1/100 of the starting 
volume in lysis buffer (PBS containing lysozyme 0.2 mg/ml, DNAse 1 
/lg/ml, Triton X-100 0.1% (v/v), PEFABLOC-SC (Pentapharm, Basel) 
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Fig. 1. Domain structure of human factor I. The heavy chain contains 
the factor I, C6, C7-specific (FIM) domain, the CD5 domain, and two 
low density lipoprotein (LDLr) domains, numbered as in [5], and iden- 
tified in [6]. The light chain contains the serine protease (SP) domain. 
Putative carbohydrate chains and the disulphide link between the light 
and heavy chains are also indicated. 
1 mM, benzamidine 50 mM, EDTA 5 mM, PBS is NaCI 150 mM, 
NazHPO4 54 mM, NaH2PO4 16 mM, pH 7.2) for 1 h followed by 
sonication 3 x 20 s on ice using an MSE sonicator. The lysate was 
clarified at 32,500 x g at 4°C for 20 rain. The supernatant was passed 
through a 2.5 x 10 cm column containing 50 ml glutathione agarose 
(Sigma), equilibrated in PBS. The column was washed with 250 ml 
Dulbecco A PBS (Oxoid) containing 1 mM EDTA pH 8.0 and the 
fusion protein was eluted with 150 ml Dulbecco A PBS containing 10 
mM reduced glutathione and 1 mM EDTA pH 8.0. The protein was 
dialysed against 50 mM Tris-HC1, 100 mM NaC1, pH 8.2 and cleaved 
with human Factor Xa (Boerhinger Mannheim) (1% w/w fusion pro- 
tein) for 6 h at 37°C. Trifluoroacetic acid (0.1% v/v) was added to the 
cleaved GST:LDLr2 fusion protein and the proteins were separated by 
reversed phase chromatography on a 3 ml Resource RPC column 
(Pharmacia) using a linear 1%99.9% acetonitrile gradient in 0.1% TFA. 
LDLr2 eluted at approximately 25% acetonitrile. The domain was 
lyophilised and resuspended in 1 ml PBS (Sigma D5773) and further 
purified through a 1.6 × 100 cm Superdex 30 prep grade (Pharmacia) 
column. The domain was concentrated by ultrafiltration using a 10 ml 
Amicon stirred cell and a YM3 membrane (Amicon). 
A polyclonal antiserum was raised to GST:LDLr2 in rabbits, and 
immunoglobulin was purified by triple 16% w/v sodium sulphate pre- 
cipitation [20]. ELISAs using GST:LDLr2 antibodies were performed 
with factor I (prepared as in [21]) or an irrelevant GST construct bound 
to microtitre plates. The GST:LDLr2 antibodies were also tested 
against reduced and unreduced factor I in Western blot analysis. 
2.3. Spectroscopic studies of LDLr2 and factor I 
Fourier transform infrared (FT-IR) spectra were recorded and analy- 
sed on a Perkin-Elmer 1750 FT-IR spectrometer as described elsewhere 
[6]. Fluorescence emission spectra were r corded with 50/.tg/ml LDLr2 
in 10 mM potassium phosphate buffer, pH 7.0 and (~6 M guanidine- 
HC1 at 20°C, using a SPEX Fluoromax spectrofluorometer with 1 cm 
pathlength quartz microcells. The excitation frequency was set at 275 
nm for maximal excitation of the Tyr residue in LDLr2. Emission 
spectra were recorded in the range 290-350 nm for each guanidine 
concentration, together witha buffer baseline to correct for the water 
Raman peak and background scattering. Circular dichroism (CD) spec- 
troscopy was performed with 0.4 mg/ml LDLr2 in 10 mM potassium 
phosphate, pH 7.0 between 5-85°C using a Jobin-Yvon CD6 spectro- 
polarimeter with 0.5 mm pathlength quartz cells. The instrument was 
routinely calibrated with an aqueous olution of recrystallised D10- 
camphosulphonic a id (0 °]%: cm : 0.308 at 290 nm). 
3. Results and discussion 
3.1. Sequence alignment and secondary structure prediction of 
the LDLr superfamily 
A total of 194 LDLr  sequences originate from five protein 
groups, i.e. the complement LDLrs (7 proteins), together with 
LDL receptors (7 proteins), LDL receptor-related proteins (3 
proteins), VLDL receptors (2 proteins), and other cell surface 
receptor proteins (4 proteins). The consensus alignment of Fig. 
2 showed that LDLr  is typically 39 residues long [9]. It is readily 
separated into five segments a to e, between which there are 
insertions that are most likely to be involved with loop struc- 
tures. Three insertions between a-b, b-c and within e are more 
variable in length than those between c-d and d-e, which are 
caused by insertions in only 2 and 3 sequences out of 194. The 
alignment showed that 19 positions are conserved to better than 
50% of the 194 sequences and 11 are conserved to better than 
90% [9]. Cys-5, -12, -17, -24, -30 and -39 are conserved in 
98-100% of the sequences, with the notable exception of LDLr 1 
of factor I in which Cys-5 and Cys-17 are omitted (and there- 
fore likely to be disulphide linked). High conservation is also 
seen for Asp/Glu-36 (100% conserved), Asp/Glu-35 (98% con- 
served), Asp/Glu-29 (93% conserved), Asp/Glu-32 (88% con- 
served), Asp/Glu-25 (81% conserved) and Asp/Glu-27 (55% 
conserved). The residues 29DCxDGSDE36 are implicated in li- 
gand binding [22], and in the LDL receptor such residues inter- 
act electrostatically with the positively charged apoprotein B 
and apoprotein E [2]. 
Averaged secondary structure predictions were calculated 
for all 194 sequences (Fig. 3) and for each of the five LDLr 
groups to show very similar outcomes. Three fl-strands each of 
length 2~, residues were well-predicted by all four predictive 
methods, with one in each of the sequence segments b, c and 
d (Fig. 2). It is notable that each predicted fl-strand is flanked 
by a sequence insertion (Fig. 3), as desired, and that a conserved 
hydrophobic residue occurs in each of the first and second 
fl-strands at positions 10 (aromatic: 90% conserved) and 18 
(aliphatic: 93% conserved), respectively. The GOR I/III, Chou- 
Fasman and PHD methods predict 21-36% fl-strand and 64~ 
79% turn/coil structure. The Chou-Fasman method occasion- 
ally predicted single or paired s-helical residues. As four such 
residues are required for a complete turn of an s-helix, these 
were disregarded. The predictions how that the five highly- 
conserved Asp/Glu residues all occur in a C-terminal region of 
turn or loop. The structure of this loop region would be stabil- 
ised by disulphide bridges formed by Cys-30 and Cys-39 and 
their partners. Conservation is high within this loop, as Asp 
rarely replaces Glu-36, and Glu rarely replaces Asp-25, -29, -32 
and -35. Calculation of averaged hydropathies or solvent acces- 
sibilities gave similar results and show that this loop region has 
a high exposure to solvent (Fig. 3). 
Fig. 2. Alignment of 194 LDLr domain sequences. For reason of brevity, mostly human sequences are shown. The alignment was based on 11 
sequences from the complement proteins (FI_, C6_, C7 , C8a_ and C8b_, C9_), 49 from LDL receptors (ldlr_), 96 from LDL receptor-related proteins 
(lrp_), 16 from very low density LDL receptors (vldlr_), 13 from gp330 (gp330_), 8 from heparan sulphate proteoglycan (PERLEC_) and 1 from the 
Japanese quail LRP (RSV_REC_). Further sequences were taken from the following organisms: C. elegans (_celeg), Japanese quail, hamster, mouse, 
rabbit, rat (_rat) and X. laevis. Consensus structure predictions were based on residue positions occupied in over 50% of the LDLr sequences. 
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>90% conservat ion  
>50% conservat ion  
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Consensus  mum]boring, 
F l _ l _human__  
F I  2_human 
C6_human 
C7 human 
CSa_human 
CSb_human 
C9 human 
ld l r _ l  human 
id l r _2_human 
ld l r _3  human 
ld l r  4_human 
ld l r _5_human 
id l r _6  human 
id l r _7_human 
I -a - ]  
1- - -5  
DPADVVCYTQKADS . . . .  
. . . . . . . . . .  CKAC . . . .  
CIPSKLCKIEEADC . . . .  
SCEPTRGCPTERGC . . . .  
SCSSSTTCVRQAQC . . . .  
DCVTNRPCGSQVRC . . . . . .  
CVPTEPCEDAEDDC . . . . . . .  
LLLAAAGTAVGDRC . . . . . . .  
. . . . . . . . .  LSVTC . . . . . .  
. . . . . . . . .  PPKTC . . . . . .  
. . . . . . . . .  PVLTC . . . . . .  
• RGLYVFQGDSSPC . . . . .  
. . . . . . . . .  AVATC . . . . . .  
. . . . . . . .  VNVTLC . . . . . .  
, . , , ,  . * ***  **  *e*  , ,  * 
[ - - -b - - - ]  [ -~- -1  [ . . . . .  d . . . . . .  ] l -o -  ] 
6 . . . . . .  14 15- -20  21 . . . . . . . . . .  34 35- -  39 
. . . PMDDPFQCVN . . . . . . . .  GKY ISQ.MKACDGINDCGDQS. .DEL  . . . . .  C 
. . . .  QGKGFHCKS . . . . . . . .  GVCIPS .QYQCNGEVDCITGE. .DEVG . . . .  C 
. . . . .  KNKPRCDS . . . . . . . .  GRCIAR.KLECNGENDCGDNS. .DERD . . . .  C 
. . . . .  GERFRCFS . . . .  
. . . . .  GQDFQCKE . . . .  
. . . .  EGFVCAQ . . . .  
. .GNDFQCST . . . .  
.ERNEFQCQD . . . .  
.KSGDFSCGG . . . .  
.SQDEFRCHD . . . .  
.GPASFQCNS . . . .  
. . .GQCISK .SLVCNGDSDCDEDS.ADEDR . . . .  C 
. .TGRCLKR.HLVCNGDQDCLDGS. .DEDD . . . .  C 
. .TGRCVNR.RLLCNGDNDCGDQS. .DEAN . . . .  C 
. . .GRCIKM.RLRCNGDNDCGDFS. .DEDD . . . . .  C 
. . .GKCISY .KWVCDGSAECQDGS. .DESQET. . .C  
.RVNRCIPQ.FWRCDGQVDCDNGS. .DEOG . . . . .  C 
. . .GKCISR.QFVCDSDRDCLDGS. .DEAS . . . . .  C 
. . .STC IPQ.LWACDNDPDCEDGS. .DEWPQR. . .C  
• .SAFEFHCLS . . . . . . . .  GECIHS.SWRCDGGPDCKDKS. .DEEN . . . . .  C 
. .RPDEFOCSD . . . . . . . .  GNCIHG.SRQCDREYDCKDMS. .DEVG . . . . .  C 
.EGPNKFKCHS . . . . . . . .  GECITL .DKVCNMARDCRDWS. .DEP IKE . . .C  
i rp_1_human_  
i rp_2_human_  
I rp_3_human_  
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l rp_5_human_  
l rp_6_human_  
l rp_7_human_  
l rp_8  human 
i rp_9_human 
l rp  10_human 
l rp  11 human 
l rp_12  human 
l rp_13_human 
l rp_14_human 
i rp  15 human 
l rp  16 human 
l rp  17 human 
i rp_18  human 
l rp  19 human 
i rp  20_human 
i rp  21_human 
i rp  22 human 
i rp  23 human 
i r  p_24_human 
i rp_25_human 
I rp  26 human 
i rp_27_human 
i rp  28 human 
I rp  29 human 
i rp  30 human 
i rp_31_human 
i rp_17  ce leg  
i rp_21_ce leg  
i rp_34_ce leg  
v ld l r  1 hum 
v ld l r  2 hum 
v ld l r  3 hum 
v ld l r  4 hum 
v ld l r  5 hum 
v ld l r  6 hum 
v ld l r  7 hum 
v ld l r  8 hum 
PERLEC_ I_hum 
PERLEC 2 hum 
PERLEC_3_hum 
PERLEC 4 hum 
GP330 1 ra t  
GP330 2 ra t  
GP330 3 ra t  
GP330 4 ra t  
SALVAAAIDAPKTC . . . . .  
. . . . . .  PQSKAqRC . . . . . .  
TCLANPSYVPPPQC . . . . . .  
. . . . . . . . .  HQHTC . . . . . .  
. . . . . . . . .  SARTC . . . . .  
. . . . . . . . .  AYPTC . . . . .  
. . . . . . . . . .  SHSC . . . . .  
. . . TNQATRPPGGC . . . . .  
. . . . . . .  EGVTHVC . . . . .  
. . . . . . . . .  ESLAC . . . . .  
LQDDLTCRAVNSSC . . . . .  
. . . . . . . .  NSRRC . . . . .  
. . . . . . . .  NKTAC . . . . .  
. . .SPKQFACRD . . . . . . .  Q ITC ISK .GWRCDGERDCPDGS. .DEAPE I . . .C  
. . .QPNEHNCLG . . . . . . .  TELCVPM.SRLCNGVQDCMDGS. .DEGPH . . . .  C 
. .QPGEFACAN . . . . . . . .  SRCIQE.RWKCDGDNDCLDNS. .DEAPAL . . .C  
. .PSDRPKCEN . . . . . . . .  NRCIPN.RWLCDGDNDCGNSE. .DESNAT. . .C  
. .PPNQFSCAS. . .  
.PPLTQFTCNN. . .  
. .SSTQFKCNS. . .  
. .HTDEFQCRL. . .  
.DPSVKFGCKD. . .  
. .RPPSHPCAN. . .  
.RAQDEFECAN. . .  
. .KKTFRQCSN. . .  
. .GVGEFRCRD. . .  
. . . .  GRCIP I .SWTCDLDDDCGDRS. .DESAS . . . .  C 
. . . .  GRCIN I .NWRCDNDNDCGDNS. .DEAG . . . . .  C 
. . . .  GRCIPE .HWTCDGDNDCGDYS. .DETHAN. . .C  
. . .DGLCIPL .RWRCDGDTDCMDSS. .DEKS . . . . .  C 
. . .SARCISK .AWVCDGDNDCEDNS. .DEEN . . . . .  C 
. .NTSVCLPP .DKLCDGNDDCGDGS. .DEGEL  . . . .  C 
. . . .  GECINF .SLTCDGVPHCKDKS. .DEKPSY. . .C  
. . . .  GRCVSN.MLWCNGADDCGDGS. .DE IP  . . . . .  C 
. . . .  GTCIGN.SSRCNQFVDCEDAS.•DEMN . . . . .  C 
. . . . . . . .  SATDCSSYFRLGVKGVLFQPCER. . .  
. . . . .  PGVKRPRC. .  
. . . . . . . .  NKFC. .  
. . . . . . . .  EGKTC. .  
. . . . . . .  LYNSTC. .  
. . . . . . .  EYPTC. .  
. . . . .  TSPEHKC.  
FYLGSDGRTCVSNC. .  
. . . . . . . . .  PEFKC. .  
. . . . . . . . .  D IHVC.  
. . . . . . . . .  PEVTC.  
. . . . . . . .  TQMTC.  
. . . . . . .  DERTC.  
. . . . . . .  TPRPC.  
. . . . . . . .  TPRC.  
. . . . .  GTGVRTC.  
. . . . . . .  ARFVC. .  
. .EPPTAHTTHC.  
. . . . . . . .  PSAVAC.  
. . . . . . . . .  GNRTC.  
. . . . . . . . .  RSAQC.  
RESGATGTGRKAKC.  
. . . . . . . . .  VKKTC.  
. . . . . . . . .  HMRTC.  
. . . . . . . . .  GNITC.  
. . . . . . . . .  APPTC.  
. . . .  GRQPVIHTKC.  
. . . . . . . . .  PSRTC.  
. . . . . . . .  KNVNQC°  
FRRLGTVPQFPRAC.  
PQPLLPGSVRPLPC.  
. . . . . . . .  GPPPPC.  
. . . . .  PTKRPEEVC.  
PYGMKLQRDQMTCC.  
. . . . . . .  GVFNNTC.  
. . . . .  PTHATSSTC.  
. . . . . . . .  QASGTC.  
. . . . . .  PLNYFACPS. . .  
. . . . . .  SEAQFECQN. .  
. . . . . .  GPSSFSCPG. . .  
. . . . . .  DDREFMCQN. . .  
o.. 
.. 
.. 
•.. 
°o 
. . .  
•°. 
°•• 
°.o 
..° 
°•• 
..o 
. . . . . .  GSLSFPCNN . . . . .  
. . . . . . .  SPSAFACVR . . . . .  
. . . . . . .  PSTSFTCDN . . . . .  
. . . . . . .  QPTQFRCPD . . . . .  
. . . TSLCYAP.SWVCDGANDCGDYS. .DERD . . . . .  C 
. . . .  GRCIPM.SWTCDKEDDCEHGE. .DETH . . . . .  C 
. . . . .  HRCISK .QWLCDGSDDCGDGS. .DEAAH . . . .  C 
. . .THVCVPE.RWLCDGDKDCADGA. .DES IAAG. .C  
. . . .  RQCIPK .HFVCDHDRDCADGS. .DESPE . . . .  C 
. . .GPSEFRCAN . . . . . . . .  GRCLSSRQWECDGENDCHDQS. .DEAPKNPH.C  
. .NASSQFLCSS . . . . . . .  GRCVAE.ALLCNGQDDCGDSS. .DERG. . .  
. . .TASQFVCKN . . . . . . .  DKCIPF .WWKCDTEDDCGDHS. .DEPPD. .  
. . .RPGQFQCST . . . . . . .  G ICTNP.AF ICDGDNDCQDNS. .DEAN. . .  
. . . LPSQFKCTN . . . . . .  TNRCIPG. IFRCNGQDNCGDGE. .DERD. . .  
. . .APNQFQCSI  . . . . . .  TKRCIPR.VWVCDRDNDCVDGS. .DEPAN. .  
. . .GVDEFRCKD . . . . . .  SGRCIPA.RWKCDGEDDCGDGS. .DEPKEE.  
. . .EPYQFRCKN . . . . . . .  NRCVPG.RWQCDYDNDCGDNS. .DEES. . .  
. . .SESEFSCAN . . . . . . .  GRCIAG.RWKCDGDHDCADGS. .DEKD. . .  
. . .DMDQFQCK8 . . . . . . .  GHCIPL .RWRCDADADCMDGS. .DEEA. . .  
. . . PLDEFQCNN . . . . . . .  TLCKPL .AWKCDGEDDCGDNS. .DENPEE.  
. .PPNRPFRCKN . . . . . .  DRVCLWI .GRQCDGTDNCGDGT. .DEED. . .  
. .KDKKEFLCRN . . . . . . .  QRCLSS.SLRCNMFDDCGDGS. .DEED. . .  
. . .AEGTFPCSN . . . . . . .  GHCINQ.TKVCDGHNDCHDEQVSDESLAT.  
. . .TDQEFHCTSNAKLAQPKYECIPR.AWLCDGDVTCAGGE. .DESTEL .  
. .DPPLRFRCAH. .  
. . .EPSQFQCTN. .  
. . .AESDFVCNN. .  
. . .R IHE ISCGA. .  
. . .SPDEFTCSS. .  
. . .GAHEFQCST. .  
. . . PASE IQCGS. .  
. . .RPDQFECED. .  
. . LGPGKFKCRS . . . . .  
. . . TEAEFACHS . . . . .  
. . .GPQEAACRN . . . . .  
. . .EPNEFPCGN . . . . .  
. . .GPTQFRCVS . . . . .  
.C 
.C 
.C 
.C 
.C 
.C 
.C 
.C 
.C 
.C 
.C 
.C 
.C 
.C 
.C 
.C 
.C 
.C 
.C 
. .C  
. . . .  SRLCLNI .LQLCNGFNDCGPNDFSDEHLSM.  
. . . . .  GRCITL .LWKCDGDEDCVDGS. .DEKN. . .  
. . . . .  GQCVPS.RWKCDGDPDCEDGS. .DESPEQ.  
. . .HSTQCIPV.SWRCDGENDCDSGE. .DEEN. . .  
. . . . .  GRCISR.NFVCNGQDDCSDGS. .DELD. . .  
. . . . .  SSC IP I .SWVCDDDADCSDQS. .DESLEQ.  
. . . . .  GECIHK.KWRCDGDPDCKDGS. .DEVN . . . . .  C 
. . . .  GSCIHG.SRQCNGIRDCVDGS. .DEVN . . . . .  C 
. .GECID I .SKVCNQEQDCRDWS. .DEPLKE. . .C  
.YNECVAL.EYRCDRRPDCRDMS. .DELN . . . . .  C 
• .GHCIPR.DYLCDGQEDCEDGS. .DELD . . . . .  C 
• .GHCALK.LWRCDGDFDCEDRT. .DEAN . . . . .  C 
• TNMCIPA.SFHCDEESDCPDRS. .DEFG . . . . .  C 
• .GKCVPS.FFRCDGVDDCHDNS. .DEXQ . . . . .  C 
• GGQCIPG.QWHCDRQNDCLDGS. .DEXK . . . . .  C 
. .HVCIPK .DWVCDTDNDCSDGS. .DEXN . . . . .  C 
• .HRCISP .LYVCDGDKDCADGS. .DEXG . . . . .  C 
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(el 194 LDLr sequences: a b 
1---5 6 . . . . . .  14 
>50% conserved .... C .... F.C.. 
GOR I TETTT TTTEETTTT 
GOR III EETTC CTTEEEETT 
CHOU-FASMAN TTTTT TTTHEETTT 
PHD LLLLL LLLLKnmemL 
Hydropathy . . .eb . .eebeb.e 
Solvent accessibil ity eeeeb . .eebeb.e 
o d e 
15--20 21 . . . . . . . . . . . . . . .  39 
G.CI.. .W.CDGD.DC.DGSDE..C 
TTEEEE EETTTTTTTTTTTTTTTTT  
TTEEEE EEEETTTCTCCTTCTTTTT 
TEEEHE EEETTTTTTTTTTTTTTTT 
LLEELL EELLLLLLLLLLLLLLLLL 
.ebb.. eb .beb. . .b .ebeee. .b  
bebbee .bebeeeeebeeeeeebe. 
(b) ii complement  LDLrs: a b c 
1---5 6 . . . . . .  14 15--20 
Fl_LDLrl_human 0KADSMDFF~VM GKYISQ 
F ILDLr2human .CKAC QGKGFHCK8 GVCIP8 
Cys-Cys br idg ing I u 1 
GOR I ETTTT TTTTTETTT TTTEEE 
GOR III CTTTT TTTEEEETT TTCEEE 
Chou-Fasman HETTT TTTEEEETT TEEEHH 
PHD LLLLL  LLLEEEELL  LEEEEE 
Hydropathy .e.eb . .e.bebee bebb.e 
Solvent accessibil ity eeeee eeeebebee eebbee 
d e 
21 . . . . . . . . . . . . . . .  39 
MEACDGINDCC~SDEL.C  
QT~MOEVDCITGEDEVGC 
u u u 
EEETTTTTTTTTTTTTTTT 
EEEETTCCCCCCCCTTTTT 
EEETTTTTTTTTTTTTTTT 
EEELLLLLLLLLLLLLLLL  
eb .bebeeebbe.eee. .b  
.b.beee.ebeeeeeeeee 
Prod lc tod  Pred ic ted  
~-s t rand  turn /co i l  
23% 77% 
36% 64% 
23% 72% 
21% 79% 
Pred ic ted  
~-s t rand  
Pred ic ted  
tu rn /©o£1 
21% 79% 
28% 72% 
28% 64% 
28% 72% 
Fig. 3. Consensus secondary structure analyses for the LDLr superfamily. The residue numbering an  alig ment is from Fig. 2. Disulphide bridges 
are indicated by 1 or u (unknown). Average predictions from (a) 194 LDLr sequences and (b) 11 complement LDLr sequences are shown (E, fl-strand; 
H, c~-helix; T, turn; C or L, coil). The total fl-strand turn/coil structure from each prediction is summarised onthe right. The hydropathy analyses 
are denoted bye for >67% hydrophilic residues and b for >67% hydrophobic residues. The PHD accessibility analyses are denoted by e (exposed) 
for >36% solvent accessibility and b (buried) for <9% solvent accessible. 
3.2. Comparison with small 13-sheet protein folds 
The 194 LDLr sequences were scored for compatibility with 
254 known protein folds. Averaging the 194 Z-scores gave the 
best values of -0.1 to -1.3 for eight folds, starting from a 
baseline of +10.0. A Z-score of less than -2.7 corresponds to 
high structural identity. Five of the 8 best-scoring folds were 
of size 46-53 residues and maintained by Cys-Cys bridges with 
short fl-strands, while three had c~-helix contents and could be 
discarded. These five folds were epidermal growth factor 
(Brookhaven code 1EGF), tissue-type plasminogen activator 
(1TPM), omega-aga-IVB toxin (1OMA), transcriptional elon- 
gation factor (1TFI), and sea anemone toxin (1ATX). The 1TFI 
fold was discarded as this is a zinc binding domain with reduced 
thiol groups. This left four folds which scored consistently 
within the top 6-14 ( + 10) of the 254. These results uggest that 
the LDLr structure has no close structural homology with 
previously determined folds, but that parts of it resembles small 
]]-sheet proteins. 
3.3. Expression and spectroscopic" characterization of LDLr2 
In factor I, LDLr2 (Fig. 1) was expressed for structural 
studies (see section 2) for reason of its greater sequence similar- 
ity with the LDLr consensus (Fig. 3). The expressed 
LDLr2:GST protein migrated at approximately 31 kDa by 
SDS-PAGE. This was purified by glutathione agarose affinity 
chromatography to yield a single product. This was used to 
raise a polyclonal antiserum, which was found to recognise 
reduced factor I heavy chain and non-reduced factor I in West- 
ern blots, and to react in an ELISA assay with factor I and 
GST. Cleavage of LDLr2:GST in solution was achieved using 
Factor Xa. LDLr2 was separated by reversed phase chroma- 
tography and purified as a single peak by gel filtration on 
Superdex 30. The N-terminal 15 amino acids were sequenced 
and determined to be the correct sequence of GIPAC- 
QGKGFHCKSG... (where the residues GIP were derived from 
the linker between GST and LDLr2). Mass spectroscopy of 
LDLr2 at pH 3.5 showed a single peak at a molecular mass of 
4099 + 1. This mass agreed precisely with that calculated from 
a 40-residue LDLr2 sequence GIPA24°CQ...DEVGCA276, in 
which the 5 Asp/Glu residues and the N-terminus are pro- 
tonated, the Cys residues are disulphide bridged, and the C- 
terminus carboxyl is ionized. Minor peaks observed at masses 
of 4138 and 4176 may correspond to the binding of one or two 
K + cations. The use of Ellman's reagent showed that no free 
thiol groups were present in non-denatured LDLr2. Therefore 
we concluded that LDLr2 has been correctly expressed. The 
existence of a folded LDLr2 structure was supported by fluo- 
rescence data. Fluorescence spectra on LDLr2 were recorded 
using 0-6 M guanidine-HC1 solutions. Theemissions at 301.0 
to 302.5 nm were plotted against guanidine concentration o 
show a sigmoidal curve, in which unfolding started at 1 M 
guanidine and ended at 4 M guanidine, after which no further 
changes were observed. 
FT-IR and CD data supported the LDLr structure predic- 
tions of Fig. 3. FT-IR spectra of LDLr2 and factor I in 2H20 
buffers (Figs. 4a and 4c) showed a broad absorbance band at 
1645 cm -1 and 1638 cm -1, respectively. Within this band, the 
second derivative spectra showed a single intense component 
at 1641 cm-1 in LDLr2 and 1637 cm-' in factor I. fl-Sheet bands 
commonly occur at 1634-1638 cm -1, with an anti-parallel 13- 
sheet component in the region of 1670-1680 cm -~ [23]. For 
LDLr2, the band at 1641 cm -1 was consistent with 13-sheet, 
while for factor I the bands at 1682 and 1637 cm -~ agreed with 
this assignment. The absence of significant absorbance in the 
region 1650-1655 cm-' indicated the lack of major a-helix 
structures inLDLr2. A minor band seen at 1649 cm -~ for factor 
I could be attributed to the single solvent-exposed a-helix of the 
SP domain (Fig. 1). 13-Turns are characterised by bands close 
to 1670 cm -~, and loop regions by bands close to 1640 cm -l [23]. 
For LDLr2, strong bands were seen at 1673 cm -~ and 1641 cm -~ 
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Fig. 4. FT-IR spectra t 20°C of LDLr2 and human factor I in 2H20 
buffers. Sample concentrations were 1.6 and 2.4 mg/ml, respectively. 
Factor I was prepared as in [24]. The (a) and (c) absorbance and (b) 
and (d) second erivative spectra re shown for each sample. 
(where the latter overlaps with the fl-sheet band), and a weak 
one at 1670 cm -1 was seen in factor I. In summary, the factor 
I spectrum (Fig. 4c and 4d) corresponded to the summation of 
a 14% contribution from two LDLrs (Figs. 4a and 4b), a 43% 
contribution from the SP domain with a known fl-sheet FT-IR 
spectrum [24], and the absence of s-helix in the F IM and CD5 
domains. CD spectra were recorded to show that LDLr2 has 
a large amount of loop or random structure and a small amount 
of fl-strand structure. The interpretation of CD spectra can 
however be affected by a large proportion of Cys residues [14], 
of which there are 6 in LDLr2. 
4. Conclusions 
The LDLr superfamily has evolved to be a key component 
of complement proteins and cell surface receptors. Despite 
many insertions into the consensus (or primordial) sequence, 
the basic fold of this domain has remained unchanged. The 
three central segments b, c and d are predicted to define the core 
structure of LDLr in terms of a fl-sheet stabilised by three 
disulphide bridges and hydrophobic residues. The disulphide 
pairing is presently unknown, but will determine the conforma- 
tion adopted by the fl-strands. It is possible to conclude from 
Fig. 3 that the biologically important Asp/Glu residues are not 
related to any fl-sheet features, and are located on an exposed 
surface loop of LDLr for ligand binding. This type of structure 
is analogous to other complement protein domains that possess 
conserved Cys residues. These structures, which include epider- 
mal growth factor [25], the SP domain [26], the short consensus/ 
complement repeat [14], and the C lq  globular heads [27], are 
all predominantly composed offl-sheet structures. 
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